Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 2,485 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 2,485 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $27.52, for a total transaction of $68,387.20. Following the transaction, the insider now owns 75,294 shares of the company’s stock, valued at approximately $2,072,090.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Catriona Yale also recently made the following trade(s):

• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total transaction of $106,684.76.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $143,052.00.

Akero Therapeutics Stock Performance

Shares of NASDAQ AKRO opened at $28.08 on Friday. The company has a 50 day simple moving average of $26.33 and a two-hundred day simple moving average of $23.96. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -8.78 and a beta of -0.26. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 12 month low of $11.25 and a 12 month high of $51.24.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. As a group, analysts predict that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on AKRO shares. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a research report on Tuesday. Wolfe Research began coverage on shares of Akero Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.13.

Hedge Funds Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its holdings in Akero Therapeutics by 2,366.0% during the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after acquiring an additional 1,183 shares during the period. Quarry LP boosted its position in Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after purchasing an additional 500 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Akero Therapeutics during the 4th quarter worth approximately $75,000. Headlands Technologies LLC lifted its stake in shares of Akero Therapeutics by 253.5% in the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after purchasing an additional 3,024 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its holdings in Akero Therapeutics by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after buying an additional 1,030 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.